

# Alexander Y Walley

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6299517/publications.pdf>

Version: 2024-02-01

150  
papers

6,987  
citations

81743

39  
h-index

66788

78  
g-index

151  
all docs

151  
docs citations

151  
times ranked

4798  
citing authors

#	ARTICLE	IF	CITATIONS
1	Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. <i>BMJ, The</i> , 2013, 346, f174-f174.	3.0	734
2	Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality. <i>Annals of Internal Medicine</i> , 2018, 169, 137.	2.0	680
3	Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. <i>Journal of Substance Abuse Treatment</i> , 2018, 85, 90-96.	1.5	233
4	Naloxone for heroin, prescription opioid, and illicitly made fentanyl overdoses: Challenges and innovations responding to a dynamic epidemic. <i>International Journal of Drug Policy</i> , 2017, 46, 172-179.	1.6	225
5	Characteristics of Fentanyl Overdose – Massachusetts, 2014–2016. <i>Morbidity and Mortality Weekly Report</i> , 2017, 66, 382-386.	9.0	219
6	Saved by the Nose: Bystander-Administered Intranasal Naloxone Hydrochloride for Opioid Overdose. <i>American Journal of Public Health</i> , 2009, 99, 788-791.	1.5	211
7	Fatal and Nonfatal Overdose Among Pregnant and Postpartum Women in Massachusetts. <i>Obstetrics and Gynecology</i> , 2018, 132, 466-474.	1.2	209
8	Office-Based Management of Opioid Dependence with Buprenorphine: Clinical Practices and Barriers. <i>Journal of General Internal Medicine</i> , 2008, 23, 1393-1398.	1.3	192
9	Addiction consultation services – Linking hospitalized patients to outpatient addiction treatment. <i>Journal of Substance Abuse Treatment</i> , 2017, 79, 1-5.	1.5	161
10	A Review of Opioid Overdose Prevention and Naloxone Prescribing: Implications for Translating Community Programming into Clinical Practice. <i>Substance Abuse</i> , 2015, 36, 240-253.	1.1	148
11	Prenatal Buprenorphine Versus Methadone Exposure and Neonatal Outcomes: Systematic Review and Meta-Analysis. <i>American Journal of Epidemiology</i> , 2014, 180, 673-686.	1.6	137
12	Overdose rescues by trained and untrained participants and change in opioid use among substance-using participants in overdose education and naloxone distribution programs: a retrospective cohort study. <i>BMC Public Health</i> , 2014, 14, 297.	1.2	125
13	Expanded Access to Naloxone Among Firefighters, Police Officers, and Emergency Medical Technicians in Massachusetts. <i>American Journal of Public Health</i> , 2014, 104, e7-e9.	1.5	125
14	Opioid overdose prevention and naloxone rescue kits: what we know and what we don't know. <i>Addiction Science &amp; Clinical Practice</i> , 2017, 12, 4.	1.2	121
15	Opioid Education and Nasal Naloxone Rescue Kits in the Emergency Department. <i>Western Journal of Emergency Medicine</i> , 2015, 16, 381-384.	0.6	116
16	Perpetuating stigma or reducing risk? Perspectives from naloxone consumers and pharmacists on pharmacy-based naloxone in 2 states. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2017, 57, S19-S27.e4.	0.7	116
17	Acute Care Hospital Utilization Among Medical Inpatients Discharged With a Substance Use Disorder Diagnosis. <i>Journal of Addiction Medicine</i> , 2012, 6, 50-56.	1.4	115
18	Touchpoints – Opportunities to predict and prevent opioid overdose: A cohort study. <i>Drug and Alcohol Dependence</i> , 2019, 204, 107537.	1.6	113

#	ARTICLE	IF	CITATIONS
19	Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort. <i>Drug and Alcohol Dependence</i> , 2019, 200, 34-39.	1.6	113
20	Estimated Prevalence of Opioid Use Disorder in Massachusetts, 2011–2015: A Capture–Recapture Analysis. <i>American Journal of Public Health</i> , 2018, 108, 1675-1681.	1.5	109
21	Sociodemographic factors and social determinants associated with toxicology confirmed polysubstance opioid-related deaths. <i>Drug and Alcohol Dependence</i> , 2019, 200, 59-63.	1.6	103
22	Opioid overdose prevention with intranasal naloxone among people who take methadone. <i>Journal of Substance Abuse Treatment</i> , 2013, 44, 241-247.	1.5	91
23	Orienting patients to greater opioid safety: models of community pharmacy-based naloxone. <i>Harm Reduction Journal</i> , 2015, 12, 25.	1.3	90
24	Prevention of Fatal Opioid Overdose. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 1863.	3.8	88
25	Emergency Medical Services Naloxone Access: A National Systematic Legal Review. <i>Academic Emergency Medicine</i> , 2014, 21, 1173-1177.	0.8	73
26	Knowledge of and interest in hepatitis C treatment at a methadone clinic. <i>Journal of Substance Abuse Treatment</i> , 2005, 28, 181-187.	1.5	70
27	Patient Perspectives of an Integrated Program of Medical Care and Substance Use Treatment. <i>AIDS Patient Care and STDs</i> , 2014, 28, 71-81.	1.1	66
28	Association of Treatment With Medications for Opioid Use Disorder With Mortality After Hospitalization for Injection Drug Use–Associated Infective Endocarditis. <i>JAMA Network Open</i> , 2020, 3, e2016228.	2.8	65
29	Post opioid overdose outreach by public health and public safety agencies: Exploration of emerging programs in Massachusetts. <i>International Journal of Drug Policy</i> , 2018, 54, 43-50.	1.6	64
30	The associations of binge alcohol use with HIV/STI risk and diagnosis among heterosexual African American men. <i>Drug and Alcohol Dependence</i> , 2009, 101, 101-106.	1.6	57
31	Prescribe to Prevent: Overdose Prevention and Naloxone Rescue Kits for Prescribers and Pharmacists. <i>Journal of Addiction Medicine</i> , 2016, 10, 300-308.	1.4	57
32	A scoping review of post opioid-overdose interventions. <i>Preventive Medicine</i> , 2019, 128, 105813.	1.6	54
33	Potentially Inappropriate Opioid Prescribing, Overdose, and Mortality in Massachusetts, 2011–2015. <i>Journal of General Internal Medicine</i> , 2018, 33, 1512-1519.	1.3	51
34	The Opioid-overdose Reduction Continuum of Care Approach (ORCCA): Evidence-based practices in the HEALing Communities Study. <i>Drug and Alcohol Dependence</i> , 2020, 217, 108325.	1.6	50
35	The HEALing (Helping to End Addiction Long-term SM) Communities Study: Protocol for a cluster randomized trial at the community level to reduce opioid overdose deaths through implementation of an integrated set of evidence-based practices. <i>Drug and Alcohol Dependence</i> , 2020, 217, 108335.	1.6	50
36	Why is it so hard to implement change? A qualitative examination of barriers and facilitators to distribution of naloxone for overdose prevention in a safety net environment. <i>BMC Research Notes</i> , 2016, 9, 465.	0.6	49

#	ARTICLE	IF	CITATIONS
37	Associations between prescribed benzodiazepines, overdose death and buprenorphine discontinuation among people receiving buprenorphine. <i>Addiction</i> , 2020, 115, 924-932.	1.7	46
38	Recent drug use, homelessness and increased short-term mortality in HIV-infected persons with alcohol problems. <i>Aids</i> , 2008, 22, 415-420.	1.0	43
39	Opioid overdose deaths and potentially inappropriate opioid prescribing practices (PIP): A spatial epidemiological study. <i>International Journal of Drug Policy</i> , 2019, 68, 37-45.	1.6	43
40	Overdose Education and Naloxone Rescue Kits for Family Members of Individuals who Use Opioids: Characteristics, Motivations, and Naloxone Use. <i>Substance Abuse</i> , 2015, 36, 149-154.	1.1	41
41	HIV-infected individuals who use alcohol and other drugs, and virologic suppression. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2017, 29, 1129-1136.	0.6	41
42	Beliefs Associated with Pharmacy-Based Naloxone: a Qualitative Study of Pharmacy-Based Naloxone Purchasers and People at Risk for Opioid Overdose. <i>Journal of Urban Health</i> , 2019, 96, 367-378.	1.8	40
43	Rejection of Patients With Opioid Use Disorder Referred for Post-acute Medical Care Before and After an Anti-discrimination Settlement in Massachusetts. <i>Journal of Addiction Medicine</i> , 2021, 15, 20-26.	1.4	38
44	Punitive policing and associated substance use risks among HIV-positive people in Russia who inject drugs. <i>Journal of the International AIDS Society</i> , 2014, 17, 19043.	1.2	37
45	Engagement and Substance Dependence in a Primary Care-Based Addiction Treatment Program for People Infected with HIV and People at High-Risk for HIV Infection. <i>Journal of Substance Abuse Treatment</i> , 2015, 59, 59-66.	1.5	37
46	Projected Estimates of Opioid Mortality After Community-Level Interventions. <i>JAMA Network Open</i> , 2021, 4, e2037259.	2.8	37
47	Association between mortality rates and medication and residential treatment after inpatient medically managed opioid withdrawal: a cohort analysis. <i>Addiction</i> , 2020, 115, 1496-1508.	1.7	36
48	HERMITAGE—a randomized controlled trial to reduce sexually transmitted infections and HIV risk behaviors among HIV-infected Russian drinkers. <i>Addiction</i> , 2015, 110, 80-90.	1.7	35
49	Methadone Dose, Take Home Status, and Hospital Admission Among Methadone Maintenance Patients. <i>Journal of Addiction Medicine</i> , 2012, 6, 186-190.	1.4	33
50	Effect of Age on Opioid Prescribing, Overdose, and Mortality in Massachusetts, 2011 to 2015. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 128-132.	1.3	33
51	Estimating naloxone need in the USA across fentanyl, heroin, and prescription opioid epidemics: a modelling study. <i>Lancet Public Health</i> , The, 2022, 7, e210-e218.	4.7	33
52	Against Medical Advice Discharges in Injection and Non-injection Drug Use-associated Infective Endocarditis: A Nationwide Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e2484-e2492.	2.9	32
53	Expanding access to naloxone for family members: The Massachusetts experience. <i>Drug and Alcohol Review</i> , 2018, 37, 480-486.	1.1	30
54	Non-fatal opioid-related overdoses among adolescents in Massachusetts 2012–2014. <i>Drug and Alcohol Dependence</i> , 2019, 194, 28-31.	1.6	30

#	ARTICLE	IF	CITATIONS
55	Characteristics and Receipt of Medication Treatment Among Young Adults Who Experience a Nonfatal Opioid-Related Overdose. <i>Annals of Emergency Medicine</i> , 2020, 75, 29-38.	0.3	29
56	Study protocol for a pragmatic trial of the Consult for Addiction Treatment and Care in Hospitals (CATCH) model for engaging patients in opioid use disorder treatment. <i>Addiction Science &amp; Clinical Practice</i> , 2019, 14, 5.	1.2	28
57	The Contribution of Prescribed and Illicit Opioids to Fatal Overdoses in Massachusetts, 2013-2015. <i>Public Health Reports</i> , 2019, 134, 667-674.	1.3	27
58	Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort. <i>Drug and Alcohol Dependence</i> , 2021, 225, 108764.	1.6	25
59	Identifying Patients for Overdose Prevention With ICD-9 Classification in the Emergency Department, Massachusetts, 2013-2014. <i>Public Health Reports</i> , 2016, 131, 671-675.	1.3	23
60	Optimising health and safety of people who inject drugs during transition from acute to outpatient care: narrative review with clinical checklist. <i>Postgraduate Medical Journal</i> , 2016, 92, 356-363.	0.9	22
61	Sexual violence from police and HIV risk behaviours among HIV-positive women who inject drugs in St. Petersburg, Russia—A mixed methods study. <i>Journal of the International AIDS Society</i> , 2016, 19, 20877.	1.2	21
62	Buprenorphine waiver uptake among nurse practitioners and physician assistants: The role of existing waived prescriber supply. <i>Journal of Substance Abuse Treatment</i> , 2020, 115, 108032.	1.5	21
63	Nondisclosure of HIV Infection to Sex Partners and Alcohol's Role: A Russian Experience. <i>AIDS and Behavior</i> , 2013, 17, 390-398.	1.4	20
64	Is cannabis use associated with HIV drug and sex risk behaviors among Russian HIV-infected risky drinkers?. <i>Drug and Alcohol Dependence</i> , 2013, 132, 74-80.	1.6	20
65	Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Mortality. <i>Annals of Internal Medicine</i> , 2019, 170, 430.	2.0	20
66	“No home to take methadone to” Experiences with addiction services during the COVID-19 pandemic among survivors of opioid overdose in Boston. <i>Journal of Substance Abuse Treatment</i> , 2022, 135, 108655.	1.5	20
67	Lessons Learned from the Expansion of Naloxone Access in Massachusetts and North Carolina. <i>Journal of Law, Medicine and Ethics</i> , 2015, 43, 19-22.	0.4	19
68	Polypharmacy and risk of falls and fractures for patients with HIV infection and substance dependence. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2018, 30, 150-159.	0.6	19
69	Chronic Opioid Therapy in People Living With Human Immunodeficiency Virus: Patients' Perspectives on Risks, Monitoring, and Guidelines. <i>Clinical Infectious Diseases</i> , 2019, 68, 291-297.	2.9	19
70	Study protocol for the targeting effective analgesia in clinics for HIV (TEACH) study—a cluster randomized controlled trial and parallel cohort to increase guideline concordant care for long-term opioid therapy among people living with HIV. <i>HIV Research and Clinical Practice</i> , 2019, 20, 48-63.	1.1	18
71	Factors associated with help seeking by community responders trained in overdose prevention and naloxone administration in Massachusetts. <i>Drug and Alcohol Dependence</i> , 2019, 204, 107531.	1.6	18
72	Assessing pharmacy-based naloxone access using an innovative purchase trial methodology. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2020, 60, 853-860.	0.7	18

#	ARTICLE	IF	CITATIONS
73	Improving the Delivery of Chronic Opioid Therapy Among People Living With Human Immunodeficiency Virus: A Cluster Randomized Clinical Trial. <i>Clinical Infectious Diseases</i> , 2021, 73, e2052-e2058.	2.9	18
74	Revisiting pharmacy-based naloxone with pharmacists and naloxone consumers in 2 states: 2017 perspectives and evolving approaches. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2020, 60, 740-749.	0.7	17
75	Comparison of Rates of Overdose and Hospitalization After Initiation of Medication for Opioid Use Disorder in the Inpatient vs Outpatient Setting. <i>JAMA Network Open</i> , 2020, 3, e2029676.	2.8	17
76	Postpartum changes in methadone maintenance dose. <i>Journal of Substance Abuse Treatment</i> , 2014, 47, 229-232.	1.5	16
77	Stuck in the window with you: HIV exposure prophylaxis in the highest risk people who inject drugs. <i>Substance Abuse</i> , 2019, 40, 441-443.	1.1	16
78	Attitudes and perceptions of naloxone dispensing among a sample of Massachusetts community pharmacy technicians. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2019, 59, 824-831.	0.7	16
79	A strengths-based case management intervention to link HIV-positive people who inject drugs in Russia to HIV care. <i>Aids</i> , 2019, 33, 1467-1476.	1.0	16
80	Rurality and differences in pharmacy characteristics and community factors associated with provision of naloxone in the pharmacy. <i>International Journal of Drug Policy</i> , 2020, 85, 102602.	1.6	16
81	Inpatient addiction consultation and post-discharge 30-day acute care utilization. <i>Drug and Alcohol Dependence</i> , 2020, 213, 108081.	1.6	16
82	Are Opioid Dependence and Methadone Maintenance Treatment (MMT) Documented in the Medical Record? A Patient Safety Issue. <i>Journal of General Internal Medicine</i> , 2009, 24, 1007-1011.	1.3	15
83	Variation in Initiation, Engagement, and Retention on Medications for Opioid Use Disorder Based on Health Insurance Plan Design. <i>Medical Care</i> , 2022, 60, 256-263.	1.1	15
84	Age-based preferences for risk communication in the fentanyl era: "A lot of people keep seeing other people die and that's not enough for them". <i>Addiction</i> , 2021, 116, 1495-1504.	1.7	14
85	Characteristics of post-overdose public health-public safety outreach in Massachusetts. <i>Drug and Alcohol Dependence</i> , 2021, 219, 108499.	1.6	14
86	Competing risks of women and men who use fentanyl: "The number one thing I worry about would be my safety and number two would be overdose". <i>Journal of Substance Abuse Treatment</i> , 2021, 125, 108313.	1.5	14
87	Identification of non-steroidal anti-inflammatory drug use disorder: A case report. <i>Addictive Behaviors</i> , 2017, 70, 61-64.	1.7	13
88	Polypharmacy and risk of non-fatal overdose for patients with HIV infection and substance dependence. <i>Journal of Substance Abuse Treatment</i> , 2017, 81, 1-10.	1.5	13
89	Opioid and cocaine use among primary care patients on buprenorphine "Self-report and urine drug tests. <i>Drug and Alcohol Dependence</i> , 2018, 192, 245-249.	1.6	13
90	Alcohol Consumption and Bone Mineral Density in People with HIV and Substance Use Disorder: A Prospective Cohort Study. <i>Alcoholism: Clinical and Experimental Research</i> , 2018, 42, 1518-1529.	1.4	13

#	ARTICLE	IF	CITATIONS
91	Provider opioid prescribing practices and the belief that opioids keep people living with HIV engaged in care: a cross-sectional study. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2019, 31, 1140-1144.	0.6	13
92	Opioid overdose and inpatient care for substance use disorder care in Massachusetts. <i>Journal of Substance Abuse Treatment</i> , 2020, 112, 42-48.	1.5	13
93	Shorter outpatient wait-times for buprenorphine are associated with linkage to care post-hospital discharge. <i>Drug and Alcohol Dependence</i> , 2021, 224, 108703.	1.6	13
94	Targeting community-based naloxone distribution using opioid overdose death rates: A descriptive analysis of naloxone rescue kits and opioid overdose deaths in Massachusetts and Rhode Island. <i>International Journal of Drug Policy</i> , 2021, 98, 103435.	1.6	13
95	Sexually transmitted infections among HIV-infected heavy drinkers in St Petersburg, Russia. <i>International Journal of STD and AIDS</i> , 2012, 23, 853-858.	0.5	12
96	Mortality in HIV-Infected Alcohol and Drug Users in St. Petersburg, Russia. <i>PLoS ONE</i> , 2016, 11, e0166539.	1.1	12
97	HIV Stigma and Substance Use Among HIV-Positive Russians with Risky Drinking. <i>AIDS and Behavior</i> , 2017, 21, 2618-2627.	1.4	12
98	Public restrooms and the opioid epidemic. <i>Substance Abuse</i> , 2020, 41, 432-436.	1.1	12
99	Warrant checking practices by post-overdose outreach programs in Massachusetts: A mixed-methods study. <i>International Journal of Drug Policy</i> , 2022, 100, 103483.	1.6	12
100	Implications of Cannabis Use and Heavy Alcohol Use on HIV Drug Risk Behaviors in Russian Heroin Users. <i>AIDS and Behavior</i> , 2008, 12, 662-669.	1.4	11
101	Risk factors for recent nonfatal overdose among HIV-infected Russians who inject drugs. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2014, 26, 1013-1018.	0.6	11
102	Older, hypertensive, and hypercholesterolemic fairgoers visit more booths and differ in their health concerns at a community health fair. <i>Journal of Community Health</i> , 2000, 25, 315-329.	1.9	10
103	Which patients receive an addiction consult? A preliminary analysis of the INREACH (INpatient) Tj ETQq1 1 0.784314 rgBT /Overlock 1035-42.	1.5	10
104	Predictors of pain-related functional impairment among people living with HIV on long-term opioid therapy. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, 33, 507-515.	0.6	10
105	Outcomes of Ottawa, Canada's Managed Opioid Program (MOP) where supervised injectable hydromorphone was paired with assisted housing. <i>International Journal of Drug Policy</i> , 2021, 98, 103400.	1.6	10
106	Integration of substance use treatment and medical care: A special issue of JSAT. <i>Journal of Substance Abuse Treatment</i> , 2012, 43, 377-381.	1.5	9
107	Heroin Use and HIV Disease Progression: Results from a Pilot Study of a Russian Cohort. <i>AIDS and Behavior</i> , 2015, 19, 1089-1097.	1.4	9
108	Marijuana Use and Its Associations With Pain, Opioid Dose, and HIV Viral Suppression Among Persons Living With HIV on Chronic Opioid Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, 195-201.	0.9	9

#	ARTICLE	IF	CITATIONS
109	Comparison of Treatment Options for Refractory Opioid Use Disorder in the United States and Canada: a Narrative Review. <i>Journal of General Internal Medicine</i> , 2020, 35, 2418-2426.	1.3	9
110	Pharmacy leaders'™ beliefs about how pharmacies can support a sustainable approach to providing naloxone to the community. <i>Research in Social and Administrative Pharmacy</i> , 2020, 16, 1493-1497.	1.5	9
111	Northeast Postacute Medical Facilities Disproportionately Reject Referrals For Patients With Opioid Use Disorder. <i>Health Affairs</i> , 2022, 41, 434-444.	2.5	9
112	Frequency and associated risk factors of non-fatal overdose reported by pregnant women with opioid use disorder. <i>Addiction Science &amp; Clinical Practice</i> , 2018, 13, 26.	1.2	8
113	Standard Fixed-Schedule Methadone Taper Versus Symptom-Triggered Methadone Approach for Treatment of Neonatal Opioid Withdrawal Syndrome. <i>Hospital Pediatrics</i> , 2019, 9, 576-584.	0.6	8
114	Effect of Publicly Reported Aortic Valve Surgery Outcomes on Valve Surgery in Injection Drug'™ and Non'™Injection Drug'™Associated Endocarditis. <i>Clinical Infectious Diseases</i> , 2020, 71, 480-487.	2.9	8
115	Pharmacist attitudes toward pharmacy-based naloxone: A cross-sectional survey study. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2020, 60, 304-310.	0.7	8
116	Broadening access to naloxone: Community predictors of standing order naloxone distribution in Massachusetts. <i>Drug and Alcohol Dependence</i> , 2022, 230, 109190.	1.6	8
117	Community'™based naloxone coverage equity for the prevention of opioid overdose fatalities in racial/ethnic minority communities in Massachusetts and Rhode Island. <i>Addiction</i> , 2022, 117, 1372-1381.	1.7	8
118	Update in Addiction Medicine for the Generalist. <i>Journal of General Internal Medicine</i> , 2011, 26, 77-82.	1.3	7
119	The Surgeon General's Facing Addiction report: An historic document for health care. <i>Substance Abuse</i> , 2017, 38, 122-122.	1.1	7
120	Predicting longitudinal service use for individuals with substance use disorders: A latent profile analysis. <i>Journal of Substance Abuse Treatment</i> , 2022, 132, 108632.	1.5	7
121	Limited access to pharmacy-based naloxone in West Virginia: Results from a statewide purchase trial. <i>Drug and Alcohol Dependence</i> , 2022, 231, 109259.	1.6	7
122	Fatal and non-fatal overdose after narcology hospital discharge among Russians living with HIV/AIDS who inject drugs. <i>International Journal of Drug Policy</i> , 2017, 39, 114-120.	1.6	6
123	Pharmacists'™ experiences with a statewide naloxone standing order program in Massachusetts: a mixed methods study. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2022, 62, 157-166.	0.7	6
124	Integrating substance use care into primary care for adolescents and young adults: Lessons learned. <i>Journal of Substance Abuse Treatment</i> , 2021, 129, 108376.	1.5	6
125	Development and Implementation of an Opioid Overdose Prevention Program Within a Preexisting Substance Use Disorders Treatment Center. <i>Journal of Addiction Medicine</i> , 2014, 8, 164-169.	1.4	5
126	Federal Policymakers Should Urgently and Greatly Expand Naloxone Access. <i>American Journal of Public Health</i> , 2022, 112, 558-561.	1.5	5



#	ARTICLE	IF	CITATIONS
127	Prescribe to Save Lives: Improving Buprenorphine Prescribing Among HIV Clinicians. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2022, 90, 546-552.	0.9	5
128	[Commentary] CAN ONE BE AN EXPERT IN ADDICTION MEDICINE WITHOUT EXPERTISE IN PAIN MANAGEMENT?. <i>Addiction</i> , 2008, 103, 2006-2007.	1.7	4
129	2012 Update in addiction medicine for the generalist. <i>Addiction Science &amp; Clinical Practice</i> , 2013, 8, 6.	1.2	4
130	HIV prevention and treatment strategies can help address the overdose crisis. <i>Preventive Medicine</i> , 2015, 80, 37-40.	1.6	4
131	It could potentially be dangerous... but nothing else has seemed to help me. Patient and clinician perspectives on benzodiazepine use in opioid agonist treatment. <i>Journal of Substance Abuse Treatment</i> , 2021, 131, 108455.	1.5	4
132	Modeling the cost-effectiveness and impact on fatal overdose and initiation of buprenorphine-naloxone treatment at syringe service programs. <i>Addiction</i> , 2022, , .	1.7	4
133	2013 Update in addiction medicine for the generalist. <i>Addiction Science &amp; Clinical Practice</i> , 2013, 8, 18.	1.2	3
134	Intranasal Naloxone for Opioid Overdose Reversal. <i>Prehospital Emergency Care</i> , 2015, 19, 135-137.	1.0	3
135	Population-level impact of initiating pharmacotherapy and linking to care people with opioid use disorder at inpatient medically managed withdrawal programs: an effectiveness and cost-effectiveness analysis. <i>Addiction</i> , 2022, 117, 2450-2461.	1.7	3
136	If we build it, will they come? Perspectives on pharmacy-based naloxone among family and friends of people who use opioids: a mixed methods study. <i>BMC Public Health</i> , 2022, 22, 735.	1.2	3
137	The Patients in Recovery (PIR) Perspective: Teaching Physicians about Methamphetamine. <i>Substance Abuse</i> , 2008, 29, 61-64.	1.1	2
138	Preventing Prescription Opioid Overdose Deaths. <i>Journal of General Internal Medicine</i> , 2013, 28, 1258-1259.	1.3	2
139	Massachusetts Health Reform's Effect on Hospitalizations with Substance Use Disorder-Related Diagnoses. <i>Health Services Research</i> , 2018, 53, 1727-1744.	1.0	2
140	Alcohol and Bone Turnover Markers among People Living with HIV and Substance Use Disorder. <i>Alcoholism: Clinical and Experimental Research</i> , 2020, 44, 992-1000.	1.4	2
141	Opioid Overdose Fatality Prevention Reply. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 873.	3.8	1
142	Comments on Strang et al. (2016): "Clinical provision of improvised nasal naloxone without experimental testing and without regulatory approval: imaginative shortcut or dangerous bypass of essential safety procedures?" <i>Addiction</i> , 2016, 111, 1879-1880.	1.7	1
143	Response to Letter to the Editor: The Contribution of Prescribed and Illicit Opioids to Fatal Overdoses in Massachusetts, 2013-2015. <i>Public Health Reports</i> , 2020, 135, 542-543.	1.3	1
144	Emergency Department Utilization Among People Living With HIV on Chronic Opioid Therapy. <i>Journal of the International Association of Providers of AIDS Care</i> , 2021, 20, 232595822110109.	0.6	1

#	ARTICLE	IF	CITATIONS
145	Treatment of Refractory Opioid Use Disorder. Journal of General Internal Medicine, 2021, 36, 1793-1793.	1.3	1
146	Naloxone receipt and overdose prevention care among people with HIV on chronic opioid therapy. Aids, 2021, 35, 697-700.	1.0	1
147	In reply:. Annals of Emergency Medicine, 2020, 75, 553-554.	0.3	0
148	SUN-540 No Effect Of Alcohol Use On Bone Microarchitecture Of The Distal Radius Among HIV Infected Adults. Journal of the Endocrine Society, 2019, 3, .	0.1	0
149	A collaborative care intervention to improve opioid prescribing among providers caring for persons with HIV: Impact on satisfaction, confidence, and trust. Drug and Alcohol Dependence, 2022, 231, 109250.	1.6	0
150	Functional Impairment and Cognitive Symptoms Among People with HIV Infection on Chronic Opioid Therapy for Pain: The Impact of Gabapentin and Other Sedating Medications. AIDS and Behavior, 0, , .	1.4	0